The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Provocative tests with psychostimulant drugs in schizophrenia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
The Pharmacological Basis for Therapeutics
JOHNS, M. E. (1981) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.1981.00790410063020 · Cited by 1,993
Molecular pathology of schizophrenia: more than one disease process?
Crow, T. J. (1980) · BMJ · doi:10.1136/bmj.280.6207.66 · Cited by 1,856
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Martin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943
The Dopamine Hypothesis of Schizophrenia: A Review*
Meltzer, H. Y., & Stahl, S. M. (1976) · Schizophrenia Bulletin · doi:10.1093/schbul/2.1.19 · Cited by 883
Snyder, S. H., Banerjee, S. P., Yamamura, H. I., & Greenberg, D. (1974) · Science · doi:10.1126/science.184.4143.1243 · Cited by 834
Amphetamine Psychosis: A "Model" Schizophrenia Mediated by Catecholamines
SNYDER, S. H. (1973) · American Journal of Psychiatry · doi:10.1176/ajp.130.1.61 · Cited by 587
The dopamine hypothesis of schizophrenia: focus on the dopamine receptor
(1976) · American Journal of Psychiatry · doi:10.1176/ajp.133.2.197 · Cited by 556
Cited by
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
Dopamine: Functions, Signaling, and Association with Neurological Diseases
Klein, M. O., Battagello, D. S., Cardoso, A. R., Hauser, D. N., Bittencourt, J. C., & Correa, R. G. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0632-3 · Cited by 1,073
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
Lahti, A. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 921
Increased dopamine transmission in schizophrenia: relationship to illness phases
Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., & Innis, R. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00067-0 · Cited by 715
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Effects of Ketamine in Normal and Schizophrenic Volunteers
Lahti, A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00243-3 · Cited by 674
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.006 · Cited by 617
Mueser, K. T., Drake, R. E., & Wallach, M. A. (1998) · Addictive Behaviors · doi:10.1016/s0306-4603(98)00073-2 · Cited by 617
van Winkel, R., Stefanis, N. C., & Myin-Germeys, I. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn101 · Cited by 489
Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies
Laruelle, M., & Abi-Dargham, A. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300405 · Cited by 461
Arinami, T. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.4.577 · Cited by 455
Glutamate, Dopamine, and Schizophrenia: From Pathophysiology to Treatment
LARUELLE, M., KEGELES, L. S., & ABI‐DARGHAM, A. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.063 · Cited by 437
Weiner, I. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1313-x · Cited by 391
Neural development, cell-cell signaling, and the “two-hit” hypothesis of schizophrenia
Maynard, T. M., Sikich, L., Lieberman, J. A., & LaMantia, A.-S. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006887 · Cited by 383
Self-citationKaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Imaging endogenous dopamine competition with [11C]raclopride in the human brain
Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Schlyer, D., Hitzemann, R., Lieberman, J., Angrist, B., Pappas, N., MacGregor, R., et al. (1994) · Synapse · doi:10.1002/syn.890160402 · Cited by 379
Self-citationKegeles, L. S., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J. J., Van Heertum, R. L., Cooper, T. B., Carlsson, A., & Laruelle, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00976-8 · Cited by 377
Meyer, U., Feldon, J., & Fatemi, S. H. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.05.001 · Cited by 373
Epidemiology-driven neurodevelopmental animal models of schizophrenia
Meyer, U., & Feldon, J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.10.018 · Cited by 372
Neurobiology of Dopamine in Schizophrenia
Guillin, O., Abi‐Dargham, A., & Laruelle, M. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78001-1 · Cited by 365
Laruelle, M. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00054-5 · Cited by 358
Amelioration of negative symptoms in schizophrenia by glycine
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1234 · Cited by 354
Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience
Kesby, J., Eyles, D., McGrath, J., & Scott, J. (2018) · Translational Psychiatry · doi:10.1038/s41398-017-0071-9 · Cited by 352
Dopamine Partial Agonists: A New Class of Antipsychotic
Lieberman, J. A. (2004) · CNS Drugs · doi:10.2165/00023210-200418040-00005 · Cited by 340
Self-citationAnimal models of psychiatric disorders
(2012) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52002-9.00009-7 · Cited by 336
Lieberman, J. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00045-6 · Cited by 333
Self-citationPsychosis pathways converge via D2High dopamine receptors
Seeman, P., Schwarz, J., Chen, J.-F., Szechtman, H., Perreault, M., McKnight, G. S., Roder, J. C., Quirion, R., Boksa, P., Srivastava, L. K., et al. (2006) · Synapse · doi:10.1002/syn.20303 · Cited by 330
Pruessner, M., Cullen, A. E., Aas, M., & Walker, E. F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.013 · Cited by 315
An integrative perspective on the role of dopamine in schizophrenia
Maia, T. V., & Frank, M. J. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.021 · Cited by 293
Targeting the dopamine D2receptor in schizophrenia
Seeman, P. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.4.515 · Cited by 302
Pathway-Specific Dopamine Abnormalities in Schizophrenia
Weinstein, J. J., Chohan, M. O., Slifstein, M., Kegeles, L. S., Moore, H., & Abi-Dargham, A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.03.2104 · Cited by 297
Schizophrenia: from phenomenology to neurobiology
Wong, A. H. C., & Van Tol, H. H. M. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(03)00035-6 · Cited by 280
Substance misuse, psychiatric disorder and violent and disturbed behaviour
Soyka, M. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.345 · Cited by 279
Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia
Abi-Dargham, A., & Moore, H. (2003) · The Neuroscientist · doi:10.1177/1073858403252674 · Cited by 277
Dopaminergic Mechanisms in Idiopathic and Drug-induced Psychoses
Lieberman, J. A., Kinon, B. J., & Loebel, A. D. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.1.97 · Cited by 274
Self-citationMethamphetamine Psychosis: Epidemiology and Management
Glasner-Edwards, S., & Mooney, L. J. (2014) · CNS Drugs · doi:10.1007/s40263-014-0209-8 · Cited by 266
Meyer, U., Murray, P. J., Urwyler, A., Yee, B. K., Schedlowski, M., & Feldon, J. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002042 · Cited by 252
Dopamine hypothesis of schizophrenia: Making sense of it all
Toda, M., & Abi-Dargham, A. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0041-7 · Cited by 235
All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors
Seeman, P. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00162.x · Cited by 228
Rethinking schizophrenia in the context of normal neurodevelopment
Catts, V. S., Fung, S. J., Long, L. E., Joshi, D., Vercammen, A., Allen, K. M., Fillman, S. G., Rothmond, D. A., Sinclair, D., Tiwari, Y., et al. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00060 · Cited by 206
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205
Self-citationGraham, J., & Coghill, D. (2008) · CNS Drugs · doi:10.2165/00023210-200822030-00003 · Cited by 185
Jongkees, B. J., Hommel, B., Kühn, S., & Colzato, L. S. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.08.014 · Cited by 183
Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179
Methyiphenidate vs. amphetamine: Comparative review
Arnold, L. E. (2000) · Journal of Attention Disorders · doi:10.1177/108705470000300403 · Cited by 164
Neural basis of psychosis-related behaviour in the infection model of schizophrenia
Meyer, U., & Feldon, J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.022 · Cited by 158
The natural history and pathophysiology of treatment resistant schizophrenia
Sheitman, B. B., & Lieberman, J. A. (1998) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00052-6 · Cited by 140
Self-citationAbi-Dargham, A., Kegeles, L. S., Zea-Ponce, Y., Mawlawi, O., Martinez, D., Mitropoulou, V., O'Flynn, K., Koenigsberg, H. W., Van Heertum, R., Cooper, T., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.018 · Cited by 128
Dalsgaard, S., Mortensen, P. B., Frydenberg, M., Maibing, C. M., Nordentoft, M., & Thomsen, P. H. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.06.004 · Cited by 121
Koethe, D., Gerth, C. W., Neatby, M. A., Haensel, A., Thies, M., Schneider, U., Emrich, H. M., Klosterkötter, J., Schultze-Lutter, F., & Leweke, F. M. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.023 · Cited by 93
Kulak, A., Cuenod, M., & Do, K. Q. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.10.020 · Cited by 90
Phencyclidine exacerbates attentional deficits in a neurodevelopmental rat model of schizophrenia
Le Pen, G., Grottick, A. J., Higgins, G. A., & Moreau, J.-L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300208 · Cited by 82
The potential role of lamotrigine in schizophrenia
Large, C. H., Webster, E. L., & Goff, D. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0020-9 · Cited by 69
Shi, S., Leites, C., He, D., Schwartz, D., Moy, W., Shi, J., & Duan, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.535203 · Cited by 61
Zavitsanou, K., Lim, C. K., Purves-Tyson, T., Karl, T., Kassiou, M., Banister, S. D., Guillemin, G. J., & Weickert, C. S. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.05.011 · Cited by 46
Robol, V., Tibber, M. S., Anderson, E. J., Bobin, T., Carlin, P., Shergill, S. S., & Dakin, S. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060951 · Cited by 37
Egerton, A., Fusar-Poli, P., & M. Stone, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799316244 · Cited by 36
Tossell, J. W., Greenstein, D. K., Davidson, A. L., Job, S. B., Gochman, P., Lenane, M., Nugent III, T. F., Gogtay, N., Sporn, A. L., & Rapoport, J. L. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.448 · Cited by 25
Implications of research on comorbidity for the nature and management of substance misuse
Mueser, K. T., Kavanagh, D. J., & Brunette, M. F. (2007) · Translation of Addictions Science Into Practice · doi:10.1016/b978-008044927-2/50063-8 · Cited by 14
Metadata
- Authors
- Lieberman, J. A., Kane, J. M., & Alvir, J.
- Venue
- Psychopharmacology
- Published
- 1987-04
- Volume
- 91
- Issue
- 4
- Pages
- 415-433
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2038409107
- Cited by
- 532
- References
- 61
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.